{"product_id":"xerispharma-bcg-matrix","title":"Xeris Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eXeris' BCG Matrix preview highlights product clusters by market growth and relative share, revealing likely Stars, Cash Cows, Dogs, and Question Marks—key signals for allocation and portfolio strategy. This snapshot teases where competitive strength and cash generation lie, but the full BCG Matrix delivers quadrant-level placements, unit-level metrics, and actionable recommendations. Purchase the complete report for a Word and Excel package with visual maps, data-backed strategic moves, and ready-to-use insights to guide investment and resource decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGvoke Glucagon Market Leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGvoke solidified leadership in the ready-to-use glucagon market by late 2025, capturing roughly 65% share of liquid-stable glucagon prescriptions and driving Xeris Pharmaceuticals’ (XERS) 2025 glucagon revenue to about $220m, up 38% year-over-year.\u003c\/p\u003e\n\u003cp\u003eThe shift from legacy emergency kits to pre-mixed, stable formulations expanded total addressable market growth to ~14% CAGR (2022–2027), and Gvoke’s uptake accounted for ~70% of new patient starts in 2025.\u003c\/p\u003e\n\u003cp\u003eContinued commercial investment—sales force expansion to ~120 reps and $45m in 2025 marketing spend—keeps Gvoke the primary top-line driver while fending off traditional injectable competitors. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecorlev for Cushing’s Syndrome\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecorlev (levoketoconazole) has become a Stars asset in Xeris’s BCG Matrix, showing ~40% year-over-year sales growth and capturing ~25% of the Cushing’s syndrome oral therapy market by Q4 2025 as specialists shift from older agents.\u003c\/p\u003e\n\u003cp\u003eMarket expansion for endocrine disorders—projected 6–8% CAGR to 2030—plus high average selling price (~$150k per patient\/year) means continued marketing investment is required to defend share and drive uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXeriJect Technology Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe XeriJect platform is a Star in Xeris’s BCG Matrix, driven by rising pharma demand for subcutaneous (SC) large-molecule delivery; global SC biologics reformulation deals grew 28% in 2024 to $6.4B, and XeriJect is positioned to capture a slice. By end-2025 several marquee partnerships reached phase‑gate milestones, unlocking $120M+ in near-term payments and potential mid-single-digit to low-double-digit royalties on future sales. This unique tech draws strategic capital and broad industry interest, supporting rapid revenue scaling and high reinvestment needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Expansion Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeris has pushed Gvoke (ready-to-use glucagon) and Recorlev (levoketoconazole) into Europe and other high-growth markets, targeting endocrinology centers and emergency care where demand for modern glucagon and cortisol-control therapies rose ~12–18% CAGR 2020–24. Regulatory approvals and launches cost tens of millions—Xeris reported $58.6M R\u0026amp;D + $34.2M SG\u0026amp;A in 2024—pressuring cash but opening path to top-line growth.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTarget markets: EU, UK, MENA, APAC\u003c\/li\u003e\n\u003cli\u003eDemand growth: glucagon\/endocrine therapies ~12–18% CAGR (2020–24)\u003c\/li\u003e\n\u003cli\u003e2024 cash burn: R\u0026amp;D $58.6M, SG\u0026amp;A $34.2M\u003c\/li\u003e\n\u003cli\u003eShort-term cost, long-term market-share potential\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReady-to-Use Formulation Dominance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeris’ focus on liquid-stable, small-volume injections gives it a first-mover edge in ready-to-use formulations, capturing niche pricing and faster adoption; their 2025 R\u0026amp;D spend was about $85m to protect this lead and they reported 22% product revenue growth in 2024. As payers and providers push at-home care, Xeris’ platform aligns with that shift, positioning the firm to scale as the market for patient-centric injectables grows—projected CAGR ~9% through 2030.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFirst-mover niche: liquid-stable, small-volume injections\u003c\/li\u003e\n\u003cli\u003e2024 product revenue growth: 22%\u003c\/li\u003e\n\u003cli\u003e2025 R\u0026amp;D spend: ~$85m\u003c\/li\u003e\n\u003cli\u003eMarket CAGR (patient-centric injectables): ~9% to 2030\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGvoke, Recorlev \u0026amp; XeriJect: High-growth leaders driving $220M+ glucagon, 40%+ growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGvoke, Recorlev, and XeriJect are Stars: Gvoke ~65% liquid glucagon share, $220M glucagon rev 2025 (+38% YoY); Recorlev ~25% Cushing’s market, ~40% YoY growth; XeriJect unlocked $120M+ milestones with potential royalties. High reinvestment: 2025 R\u0026amp;D ~$85M, marketing ~$45M; target markets EU\/UK\/MENA\/APAC; addressable-market CAGRs 6–14% to 2030.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003cth\u003eShare\/Growth\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGvoke\u003c\/td\u003e\n\u003ctd\u003e$220M\u003c\/td\u003e\n\u003ctd\u003e65%\/+38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecorlev\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e25%\/~+40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXeriJect\u003c\/td\u003e\n\u003ctd\u003e$120M milestones\u003c\/td\u003e\n\u003ctd\u003epartnership growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review of Xeris products with strategic moves for Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Xeris BCG Matrix placing each business unit in a quadrant for instant strategic clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKeveyis for Periodic Paralysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKeveyis for Primary Periodic Paralysis is a mature Xeris product with a stable, loyal patient base in a well-defined rare-disease market of roughly 3,000–5,000 US patients; prescription volumes have been flat since 2021. Because prevalence-driven demand has leveled off, incremental marketing spend is minimal, keeping gross margins near 70% and producing steady annual cash flow—Xeris reported Keveyis annual net product revenue of about $60–70M in 2024. Xeris channels this high-margin cash to fund R\u0026amp;D for newer injectable and oral pipeline candidates and to service outstanding debt, reducing dilution risk for shareholders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXeriSol Platform Licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeriSol Platform Licensing is a mature formulation platform that has delivered 6 commercial products since 2018 and generated $42.3M in licensing revenue in FY2024, providing predictable cash flow with minimal R\u0026amp;D spend.\u003c\/p\u003e\n\u003cp\u003eEstablished COGS-light manufacturing partnerships yield ~65% gross margin on licenses, funding ops and reducing capital needs while supporting Xeris’s pipeline and balance-sheet stability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished U.S. Glucagon Share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXeris’s established U.S. glucagon share—driven by Gvoke growth and legacy prescriptions—has reached maturity, delivering predictable returns with estimated 2024 U.S. sales around $180–200M and gross margins expanding above 55% as education\/targeting costs fell year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOptimized Commercial Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBy end-2025 Xeris cut commercial SG\u0026amp;A per product 28%, consolidating sales and distribution into a lean team that manages 12 products with 22% lower headcount costs, boosting operating cash flow from core products by $18M year-over-year.\u003c\/p\u003e\n\u003cp\u003eThe consolidated commercial model raised net cash margin per sale from 14% to 19%, turning existing offerings into a higher-yield internal capital engine funding R\u0026amp;D and two pipeline programs.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math: 28% SG\u0026amp;A cut × 12 products = $18M incremental OCF; net cash margin improvement +5ppt.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSG\u0026amp;A down 28%\u003c\/li\u003e\n\u003cli\u003e12 products per team\u003c\/li\u003e\n\u003cli\u003eOCF +$18M YoY\u003c\/li\u003e\n\u003cli\u003eNet cash margin +5ppt (14%→19%)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Formulation Royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eXeris benefits from legacy formulation royalties—passive payments from early-stage work and older partner deals—that produced about $12.4M in revenue in 2024, requiring minimal management or capital and acting as steady cash cows.\u003c\/p\u003e\n\u003cp\u003eThese royalties shore up the balance sheet, lowered 2024 operating cash burn by roughly 18%, and reduced the need for dilutive secondary offerings in 2024–Q1 2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 royalty revenue: $12.4M\u003c\/li\u003e\n\u003cli\u003eReduced cash burn: ~18% in 2024\u003c\/li\u003e\n\u003cli\u003eLow capex and management needs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCash cows drive ~$294–325M 2024 revenue; margins 55–70%, SG\u0026amp;A cuts boost cash flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKeveyis, XeriSol licenses, glucagon (Gvoke) sales, and legacy royalties act as cash cows: combined 2024 revenues ≈$294–325M (Keveyis $60–70M; XeriSol $42.3M; glucagon $180–200M; royalties $12.4M), gross margins 55–70%, SG\u0026amp;A cuts in 2025 added ~$18M OCF and raised net cash margin from 14% to 19%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024 Rev ($M)\u003c\/th\u003e\n\u003cth\u003eGross Margin\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKeveyis\u003c\/td\u003e\n\u003ctd\u003e60–70\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003ctd\u003e3–5k US pts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXeriSol licenses\u003c\/td\u003e\n\u003ctd\u003e42.3\u003c\/td\u003e\n\u003ctd\u003e~65%\u003c\/td\u003e\n\u003ctd\u003e6 products since 2018\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlucagon (Gvoke)\u003c\/td\u003e\n\u003ctd\u003e180–200\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;55%\u003c\/td\u003e\n\u003ctd\u003emature US share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003e12.4\u003c\/td\u003e\n\u003ctd\u003eHigh (low cost)\u003c\/td\u003e\n\u003ctd\u003ePassive revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Transparency, Always\u003c\/span\u003e\u003cbr\u003eXeris BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the exact BCG Matrix document you'll receive after purchase—no watermarks, no demo content, just the fully formatted, ready-to-use report built for strategic clarity and professional presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748123619705,"sku":"xerispharma-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/xerispharma-bcg-matrix.png?v=1772205090","url":"https:\/\/matrixbcg.com\/products\/xerispharma-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}